Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Rapid Novor Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to multiple distinct examiners and 2 distinct art units. This suggests that the company's protein sequencing or related innovations are being reviewed in different specialized divisions of the USPTO.
HOFFMAN, ALEXANDER JOSEPH is the busiest examiner for the company, holding 1 pending office action. With multiple distinct examiners each handling a single pending office action, the workload is evenly split. This distribution allows the company to receive feedback from different perspectives within the biotechnology examination corps.
The involvement of 2 distinct art units for the pending actions indicates that the company must monitor separate units for distinct examination trends. Each unit may have its own set of priorities and procedural expectations that could impact the prosecution timeline. Developing a tailored strategy for each of the pending office actions will be essential for achieving favorable outcomes.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOFFMAN, ALEXANDER JOSEPH | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681198 | SYSTEMS AND METHODS FOR ANTIBODY CHAIN PAIRING | HOFFMAN, ALEXANDER JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681198 | SYSTEMS AND METHODS FOR ANTIBODY CHAIN PAIRING | HOFFMAN, ALEXANDER JOSEPH | 1677 | §103§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRapid Novor Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alexander Joseph Hoffman has the most, with 1 of Rapid Novor Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
